The reason it failed the RA study is because the anti inflammatory effect waned over time based on the CRP marker like I predicted when we had a debate on 797. If you look at the pain score it seems like the VAS is in a trend of moving towards placebo as well. I would bet that if the trial was extended the pain relief effect would be gone as well. I think you are right that with that extra 28M the management might as well run a trial that is very likely gonna be positive to please investors, but I doubt that data will be useful for partnering. And as for the acute use, I am not sure how it can differentiate itself from celecoxib. If you recall the dental pain trial they ran, celecoxib seems to work a bit better. I remember they were contemplating its use after orthopedic surgery since NSAID cannot be used in that setting, but the management stopped talking about it after its failure in RA. BTW I own 10k ARRY shares at 2.80.
Market Data 
Markets 
AI
